Format

Send to

Choose Destination
BMC Complement Altern Med. 2017 Jul 28;17(1):375. doi: 10.1186/s12906-017-1871-4.

Effect of a herbal extract powder (YY-312) from Imperata cylindrica Beauvois, Citrus unshiu Markovich, and Evodia officinalis Dode on body fat mass in overweight adults: a 12-week, randomized, double-blind, placebo-controlled, parallel-group clinical trial.

Author information

1
Department of Family Medicine, Seoul Paik Hospital, College of Medicine, Inje University, Mareunnaero 9, Jung-gu, Seoul, 04551, Korea.
2
Institute for Clinical Nutrition, Inje University, Seoul, Korea.
3
Department of Family Medicine, Seoul Paik Hospital, College of Medicine, Inje University, Mareunnaero 9, Jung-gu, Seoul, 04551, Korea. fmleader@nuri.net.
4
Institute for Clinical Nutrition, Inje University, Seoul, Korea. fmleader@nuri.net.
5
YuYu Pharma, Inc., Yuyu Building, 197 Dongho-ro, Jung-gu, Seoul, Korea.

Abstract

BACKGROUND:

YY-312 is a herbal extract powder from Imperata cylindrica Beauvois, Citrus unshiu Markovich, and Evodia officinalis Dode, which have health promoting effects, including body fat reduction. We aimed to evaluate the efficacy and safety of YY-312 for body fat reduction in overweight adults.

METHODS:

This was a 12-week, randomized, double-blind, placebo-controlled, parallel-group clinical trial performed in overweight Korean adults aged 19-60 years with a body mass index of 25.0-29.9 kg/m2. The daily dose of YY-312 was 2400 mg (containing 1800 mg of active herbal extract and 600 mg of cyclodextrin). Primary outcomes were reductions in body fat mass (BFM) and body fat percentage (BF%) after 12 weeks. Secondary outcomes included reductions in body weight and waist circumference (WC) after 12 weeks.

RESULTS:

After 12 weeks, BFM (1.6 kg vs. 0.1 kg; P = 0.023) and BF% (1.5% vs. -0.2%; P = 0.018) decreased significantly more in the YY-312 group than in the placebo group, as did body weight (2.7 kg vs. 1.0 kg; P = 0.014) and WC (2.2 cm vs. 0.8 cm; P = 0.049). All safety parameters were within normal limits; no serious adverse events occurred in either group.

CONCLUSIONS:

In a 12-week clinical trial in overweight adults, YY-312 resulted in significantly greater reduction in body fat vs. placebo, while being safe and well tolerated.

TRIAL REGISTRATION:

cris.nih.go.kr: ( KCT0001225 ).

KEYWORDS:

Anti-obesity agents; Citrus unshiu Markovich; Evodia officinalis Dode; Imperata cylindrica Beauvois; Overweight; Weight loss

PMID:
28754119
PMCID:
PMC5534109
DOI:
10.1186/s12906-017-1871-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center